Read the latest research and articles about stem cell therapy and regenerative medicine.
Patient-derived stem cell therapy trial for geographic atrophy launches
December 17, 2019 - A clinical trial testing the safety of a patient-specific stem cell-based therapy for the treatment of geographic atrophy has been launched by the National Institutes of Health, according to a press release.
Wharton’s jelly (WJ) is a gelatinous tissue within the umbilical cord that contains myofibroblast-like stromal cells. A unique cell population of WJ that has been suggested as displaying the stemness phenotype is the mesenchymal stromal cells (MSCs).
Concise Review: Wharton’s Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cell
The umbilical cord has become an increasingly used source of mesenchymal stromal cells for preclinical and, more recently, clinical studies. Despite the increased activity, several aspects of this cell population have been under-appreciated.
Umbilical Cord Tissue for Research and Clinical Application
Variations in allogeneic mesenchymal stem cell harvest levels from human tissues reflect the evolving nature of the field, patient demographic characteristics, and differences in harvest and isolation techniques. At present,Wharton’s jelly tissue yields the highest concentration of allogeneic mesenchymal stem cells.
Pluripotent stem cells have the remarkable self-renewal ability and are capable of differentiating into multiple diverse cells. There is increasing evidence that the aging process can have adverse effects on stem cells. As stem cells age, their renewal ability deteriorates and their ability to differentiate into the various cell types is altered.
Consequences of Telomere Shortening During Lifespan
Telomerase expression is restricted in human cells and so telomeres shorten throughout our lives, providing a tumor suppressor mechanism that limits cell proliferation. As a trade-off, continuous telomere erosion results in replicative senescence and contributes to aging.